Shenogen is a new drug discovery and development venture focused on the discovery and development of small molecule and biologic drugs targeted at the novel Estrogen Receptor (ER) variant we have recently discovered and characterized. Estrogen signaling is involved in a number of diseases with big market indications such as breast cancer, prostate cancer and osteoporosis.  By leveraging our unique combination of expertise on traditional Chinese herbal formulations with long history of human usage and our proprietary receptor-based bioassays, we have screened and identified a number of naturally derived bioactive chemical compounds specifically targeting the novel ER receptor. Based on the chemical structures of these lead compounds, we are developing a pipeline of drug candidates targeting estrogen-related disease indications.

Shenogen's main operation is based in Beijing, China, taking advantage of low cost development and rich clinical resources in China. Recently, we have successfully established proof of concept and conducted preclinical studies for our two lead compounds.  We are soon moving our lead molecules targeting breast cancer treatment into phase I of human clinical trial, while candidate molecules for other indications are closely following in the pipeline. Our long term goal is to become the No.1 modern pharmaceutical company in China and to successfully develop and market a number of unique blockbuster drugs domestically and internationally.  

The name "Shenogen" comes from combining "Shen Nong" and "Gen". "Shen Nong" is the name of an ancient Chinese who pioneered traditional Chinese herbs, and "Gen"represents the latest biotechnology and medical sciences. At Shenogen, traditional Chinese herbs meet modern Western medical technology; we develop better medicines differently.